- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1412KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 146KB)
Daratumumab – July 2020
Daratumumab: 100 mg/5 mL injection, 5 mL vial, 400 mg/20 mL injection, 20 mL vial; Darzalex®
Last updated
30 October 2020